A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).

Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.

Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.

Placebo administered as 3 SC injections with the 1.0 mL glass PFS.